BMS 354825 hydrochloride manufacturers
|
| | BMS 354825 hydrochloride Basic information |
| Product Name: | BMS 354825 hydrochloride | | Synonyms: | BMS 354825 hydrochloride;BMS354825 hydrochloride;BMS-354825 hydrochloride;Dasatinib (hydrochloride);Sprycel hydrochloride;Dasatinib hydrochloride
(BMS-354825 hydrochloride;BMS-354825 HYDROCHLORIDE;BMS354825 HYDROCHLORIDE;BMS 354825 HYDROCHLORIDE;BMS-354825 HYDROCHLORIDE; SPRYCEL HYDROCHLORIDE; BMS354825 HYDROCHLORIDE; BMS 354825 HYDROCHLORIDE | | CAS: | 854001-07-3 | | MF: | C22H27Cl2N7O2S | | MW: | 524.47 | | EINECS: | | | Product Categories: | | | Mol File: | 854001-07-3.mol |  |
| | BMS 354825 hydrochloride Chemical Properties |
| Melting point | 279-280 °C | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO : 15 mg/mL (28.60 mM; Need ultrasonic and warming)H2O : 10 mg/mL (19.07 mM; Need ultrasonic) | | form | Powder | | color | White to off-white |
| | BMS 354825 hydrochloride Usage And Synthesis |
| Uses | Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib hydrochloride also induces apoptosis and autophagy. | | in vivo | Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels[1].
Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. Dasatinib (10 mg/kg) demonstrates favorable half-lives (t1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (Fpo) in this study is 27%[1]. | Animal Model: | Nude mice bearing K562 xenografts
| | Dosage: | 5 mg/kg and 50 mg/kg | | Administration: | Oral administration on a 5 day on and 2 day off schedule. | | Result: | Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed. |
| Animal Model: | Sprague-Dawley Rats
| | Dosage: | 10 mg/kg (Pharmacokinetic Analysis) | | Administration: | Oral and i.v. | | Result: | Cmax of 13.2 and 0.5 μM for i.v. and oral, respectively. |
| | IC 50 | Bcr-Abl: 1.0 nM (IC50); Src: 0.5 nM (IC50); lck: 0.4 nM (IC50); Yes: 0.5 nM (IC50); c-kit: 5.0 nM (IC50); PDGFRβ: 28 nM (IC50); p38: 100 nM (IC50); Her1: 180 nM (IC50); Her2: 710 nM (IC50); FGFR-1: 880 nM (IC50); MEK: 1700 nM (IC50) | | References | [1] Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61. DOI:10.1021/jm049486a |
| | BMS 354825 hydrochloride Preparation Products And Raw materials |
|